UK markets close in 7 hours 39 minutes

  • FTSE 100

    6,880.08
    -35.67 (-0.52%)
     

  • FTSE 250

    22,157.69
    -93.57 (-0.42%)
     

  • AIM

    1,234.32
    -2.18 (-0.18%)
     

  • GBP/EUR

    1.1561
    +0.0051 (+0.44%)
     

  • GBP/USD

    1.3729
    +0.0024 (+0.17%)
     

  • BTC-GBP

    44,254.57
    +443.11 (+1.01%)
     

  • CMC Crypto 200

    1,303.48
    +75.94 (+6.19%)
     

  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     

  • DOW

    33,800.60
    +297.00 (+0.89%)
     

  • CRUDE OIL

    58.78
    -0.54 (-0.91%)
     

  • GOLD FUTURES

    1,740.40
    -4.40 (-0.25%)
     

  • NIKKEI 225

    29,538.73
    -229.33 (-0.77%)
     

  • HANG SENG

    28,421.54
    -277.26 (-0.97%)
     

  • DAX

    15,229.12
    -5.04 (-0.03%)
     

  • CAC 40

    6,169.30
    -0.11 (-0.00%)
     
COVID Rules:

UK economy partially reopens as next stage of lockdown lift enacted

Outdoor areas in pubs and restaurants, hairdressers, gyms and non-essential retailers will be open for the first time in months today in England

Watch live: Medical examiner who performed George Floyd's autopsy expected to testify in Derek Chauvin trial

The trial of former police officer Derek Chauvin, who has been charged with murder in the death of George Floyd, continues in Minneapolis.

Latest stories

  • How Prince Harry Can Attend Prince Philip's Funeral On Saturday

    The Duke of Sussex is now believed to be quarantining in the UK

  • Man Group PLC : Form 8.3 - Gamesys Group plc

    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeGamesys Group plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure09/04/2021(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”YES / NO / N/AIf YES, specify which: OFFEROR Bally’s Corporation 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 10p ordinary InterestsShort positionsNumber%Number%(1) Relevant securities owned and/or controlled: 100,978 0.0922 - 0(2) Cash-settled derivatives: 225,171 0.2056 - 0(3) Stock-settled derivatives (including options) and agreements to purchase/sell: - 0 - 0 TOTAL: 326,149 0.2978 - 0 All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant securityPurchase/sale Number of securitiesPrice per unit (b) Cash-settled derivative transactions Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit10p ordinaryEquity SwapsReducing a long position77019.28 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) Exercise Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” (c) Attachments Is a Supplemental Form 8 (Open Positions) attached?YES/NO Date of disclosure:12/04/2021Contact name:Abdi MusseTelephone number:+442071443164 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

  • ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases

    - Company forms international consortium with ProteoGenix SAS and Amsterdam UMC Schlieren (Zurich Area), Switzerland – April 12, 2021 – ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands). “The competitive funding underlines the innovative potential of our approach to develop HLA-based therapeutics addressing multiple targets via a single fusion protein,” said Sean R. Smith, CEO of ImmunOs Therapeutics AG. “The goal of the consortium is the delivery of OCi, a novel monoclonal antibody to treat immune-mediated inflammatory diseases based on our technology platform. We plan to show our proof-of-concept in spondyloarthritis treatment. OCi will target a causative mechanism of inflammation. It works upstream of all current therapies that only 30-50% of patients respond to.” “The OCi mAb is a new product with a completely novel mechanism of action ensuring superior safety and efficacy,” said Dr. Osiris Marroquin Belaunzaran, CSO of ImmunOs. “The new antibody is expected to work in a large variety of immune-mediated inflammatory diseases where HLA-OCs trigger disease. The consortium is planning to develop OCi for psoriasis and inflammatory bowel disease once we achieve in vivo proof-of-concept in spondyloarthritis.” Within the consortium, ProteoGenix, a leader in the field of molecular immunology with 50 active antibody development projects and the largest human naïve phage display library available in Europe, will optimize its phage display technology for the HLA mAb development. “We are thrilled about the opportunity to partner with ImmunOs Therapeutics AG and Amsterdam UMC in this challenging project,” said Philippe Funfrock, CEO of ProteoGenix. “Optimizing our phage display platform for HLA mAb development will certainly serve as a basis for the development of immunotherapies targeting other equally complex inflammatory diseases using completely animal-free approaches.” Amsterdam UMC is a leading medical centre and translational research institution. The department of Clinical Immunology and Rheumatology specializes in autoimmune and immune-mediated inflammatory diseases. Among others, it will contribute its animal model of spondyloarthritis, including know-how on treatment regimens, phenotype/tissue and HLA expression and TCR repertoire analysis and provide access to an internationally recognized pool of KOLs with specific expertise on spondyloarthritis and other immune-mediated inflammatory diseases. ### About ImmunOs Therapeutics AG ImmunOs Therapeutics AG focuses on the development of a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases. The Company has established a proprietary R&D platform for the development of HLA-based therapeutics addressing multiple targets via a single fusion protein. Its novel compounds are fully human and modulate the innate immune system. ImmunOs Therapeutics´ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and activates anti-tumor responses. ImmunOs Therapeutics AG is supported by top-tier investors such as Pfizer Ventures, BioMed Partners, Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd and UZH Life Sciences Fund as well as undisclosed private investors. The Company is a spin-off from the Universities of Zurich and Basel and based in Schlieren, Switzerland. For more information, please visit www.immunostherapeutics.com About ProteoGenixProteoGenix is a biotech contract research organization (CRO) providing flexible end-to-end solutions for the discovery and development of life-saving biologics, precision diagnostic tools, and robust reagents for research. As a global leader in antibody, protein, peptide, and gene production, ProteoGenix aims at fostering the development of next-generation immunotherapies by leveraging the power of phage display technologies and combining antibody development with a strong focus on developability. For more information, please visit www.proteogenix.science. About Amsterdam UMCAmsterdam UMC, merged in 2018 from the Academic Medical Center (AMC) and the VU University Medical Center (VUmc), is a leading medical centre that combines complex patient care, scientific research and education. The 8 research institutes of Amsterdam UMC focus on specializations like Infection & Immunity, Cardiovascular Sciences and Neuroscience. For more information, please visit www.amsterdamumc.com. Company ContactImmunOs Therapeutics AG Wagistrasse 148952 Schlieren (Zurich Area), Switzerlandinfo@immunostherapeutics.com Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64 /Tel. +49 30 23 63 27 68

  • Social media not a burden for shooting star Amber Hill ahead of Tokyo push

    Shooting star Amber Hill says she won't shy away from using social media for a positive purpose in the absence of British fans at Tokyo 2020.

  • Man Fatally Shot By Police Near Minneapolis During Traffic Stop, Sparking Protests

    The shooting comes amid the ongoing trial of former police officer Derek Chauvin following the death of George Floyd.

  • Is this 'Bridgeton' heartthrob the new Black Panther for Marvel?

    Black Panther or James Bond?

  • Beauty treatments from midnight and pub gardens open as lockdown eases

    Secret Spa co-owner Emily Ewart-Perks said Monday is set to double the company’s best-ever day to date in terms of bookings.

  • UK economy partially reopens as next stage of lockdown lift enacted

    Prime minister Boris Johnson reminded people to "behave responsibly" while warnings from scientists over the weekend suggested that restrictions might be easing too quickly.

  • French residents 55 and over eligible for Covid-19 vaccines

    French nationals and residents aged 55 and above will have access to the AstraZeneca and Johnson & Johnson Covid-19 vaccines starting Monday, French Health Minister Olivier Véran said over the weekend. France is also prolonging the period between the first and second shots of the Pfizer/BioNTech and Moderna vaccines, he added. All French nationals and residents aged 55 and above will be granted access to Covid-19 vaccinations starting Monday, said Véran in an interview with the Sunday weekly Journal du Dimanche (JDD).The AstraZeneca vaccine as well as the one-shot Johnson & Johnson – which arrives in France Monday, a week ahead of schedule – will be available to those in the 55-and-above age bracket, said Véran.The shortened timeline comes as France is trying to increase the pace of its vaccination programme, which has been criticised as sluggish, and to gain ground on the spread of the more contagious virus variant first identified in Britain.At the same time, French officials have defended their policy of reserving the AstraZeneca vaccine for people over 55 with serious health problems after rare but serious blood clot disorders were observed only among younger vaccinated patients.On March 12, France authorised the use of the Johnson & Johnson vaccine, manufactured by Janssen Pharmaceuticals, a Belgium-based company owned by Johnson & Johnson. The first delivery of 200,000 doses was to arrive a week ahead of schedule, said Véran, adding, "We are expanding the vaccination campaign."France's vaccine rollout is hitting its stride after a glacial start, reaching a target of 10 million first doses a week ahead of a mid-April target. The government aims to deliver another 10 million first shots by mid-May.Extended spacing between shots for mRNA vaccinesVéran also announced an increased spacing between the first and second doses of the messenger-RNA vaccines made by Pfizer/BioNTech and Moderna.Beginning Wednesday, all those who have received the first jab will get a second one after 42 days instead of the current 28 days. “This will allow us to vaccinate faster without seeing a reduction in protection," explained Véran.Although France's top health authority advised a six-week period between the two shots in January in order to stretch supplies, the government at the time said there was insufficient data on how well the vaccines performed with a longer interval.France could safely stretch the interval now because it was vaccinating a younger age group, Véran said.Pfizer/BioNTech and Moderna vaccination campaigns moved forwardMeanwhile the vaccination campaigns with the Pfizer/BioNTech and Moderna jabs for the above-60 age group have been moved forward to Friday.The campaigns initially only targeted the most fragile groups, including those aged over 75 or anyone with comorbidities.The programme however was delayed due to procurement problems. Nearly 75 percent of nursing home residents nationwide have received two vaccine doses, but that figure falls to 35 percent among 75-79 year-olds in major cities and towns.The announcement came as France is under tightened Covid-19 restrictions with schools closed for two weeks, a ban on travel between regions and a 7pm nationwide curfew.President Emmanuel Macron, who was forced by a spiralling infection rate and overloaded healthcare system to impose a third nationwide lockdown, is counting on an accelerated vaccine rollout to allow a gradual reopening of the country from the middle of next month.The numbers in intensive care continue to rise and France will almost certainly surpass 100,000 Covid-19 deaths this week. It reported over 43,000 new cases on Saturday and said there were now 5,769 patients receiving critical care.However, Véran said there were signs that a new lockdown was beginning to slow the infection rate."It remains very high," Véran told the JDD. "We can expect that after a period of stabilisation comes the fall. But for that, we must keep going."(FRANCE 24 with AFP and REUTERS)

  • Cyclone damages Australian towns and cuts power to 31,500

    A destructive cyclone damaged several towns on Australia's western coast, shattering windows, snapping trees and knocking out power. Tropical Cyclone Seroja crossed the Western Australia state coast south of the tourist town of Kalbarri with winds gusting up to 170 kph (106 mph) shortly after dark Sunday, officials said on Monday. Around 70% of buildings in Kalbarri, a town of 1,400 people 580 kilometers (360 miles) north of the state capital Perth, had been damaged, Department of Fire and Emergency Services Commissioner Darren Klemm said.

  • Iran, nucleare: Zarif accusa Israele di sabotaggio e promette vendetta

    Il ministro degli Esteri iraniano Mohammad Javad Zarif ha accusato Israele per l'atto di sabotaggio contro la centrale nucleare di Natanz, promettendo vendetta. Lo riporta la televisione di Stato iraniana. "I sionisti vogliono vendicarsi perché abbiamo compiuto progressi nella revoca delle sanzioni e hanno detto pubblicamente che non lo permetteranno. Ma ci prenderemo la nostra vendetta", ha detto Zarif. L'incidente nell'impianto nucleare di Natanz può essere considerato un "crimine contro l'umanità", ha quindi affermato il portavoce del ministero degli Esteri iraniano, Saeed Khatibzadeh, durante una conferenza stampa trasmessa da Press Tv, durante la quale non ha risparmiato accuse a Israele. "Quello che è accaduto a Natanz è stato uno sfrontato atto di terrorismo nucleare sul suolo iraniano - ha affermato rispondendo a una domanda - Non sono state segnalate vittime né contaminazioni. Ma avrebbe potuto essere situazione catastrofica". Quanto accaduto "può essere considerato nella categoria dei crimini contro l'umanità che il regime israeliano commette ormai da molti anni. L'Iran - ha detto - si riserverà tutti i diritti di rispondere in base all'articolo 51 della Carta delle Nazioni unite. Abbiamo avviato contatti con le autorità internazionali e le Nazioni Unite". Israele ha avuto un ruolo nel sabotaggio della centrale nucleare di Natanz, in Iran, sostengono due fonti dell'intelligence americana citate dal New York Times, mentre sui media israeliani si afferma che l'esplosione ha causato "gravi danni al cuore del programma di arricchimento dell'Iran". Il New York Times stima che il programma di arricchimento dell'uranio di Teheran è stato rallentato di nove mesi. L'emittente israeliana Kan ha citato un funzionario a condizione di anonimato secondo Natanz ha subito un danno "esteso" e che sono state danneggiare varie centrifughe installate nel centro sotterraneo.

  • European stock markets lacklustre as shops reopen across England

    Today marks the first day in months that non-essential retailers and outdoor hospitality venues have been allowed to reopen in England and Wales, including indoor leisure facilities such as gyms, hairdressers, pubs and restaurants and zoos and theme parks.

  • French officials among seven Catholic clergy kidnapped in Haiti

    Two French and five Haitian religious officials as well as three civilians were kidnapped on the Caribbean island on Sunday as they were preparing to attend the inauguration of a new parish priest near Port-au-Prince. Kidnappers demanded a ransom of one million dollars. The group was kidnapped in the commune of Croix-des-Bouquets near the capital Port-au-Prince, where they were preparing to attend the installation of a new parish priest, Father Loudger Mazile, spokesperson of the island’s Bishop’s Conference, told AFP agency.The French members of the group included a priest and nun, while the Haitian group included four priests and one nun. The three civilians are associates of a priest who was not among those kidnapped. Mazile said a ransom of one million dollars was demanded for their release. A police source told AFP investigators suspected the kidnapping to be the work of an armed gang called 400 Mawozo. France’s ambassador to Haiti had not commented as of Monday morning.Gang violence increasesKidnappings and demands for ransoms have surged in recent months, both in the capital and in rural areas, reflecting the growing influence of armed gangs in the Caribbean nation. “[We express] deep sadness but also anger in regard to the inhuman situation that we have been facing for more than a decade,” read a statement issued by the Haitian Conference of the Clergy.“Not a day goes by without tears and clenched teeth, yet the so-called leaders of this country, while clinging to power, are more and more powerless.”Last month, Haiti’s government declared a month-long state of emergency to restore state authority in areas that have seen a surge in kidnappings, theft, looting and clashes with security forces in many districts. The rise in gang violence and political instability have recently drawn public demonstrations to the streets of Port-au-Prince, including on 3 April, which hundreds of women rallied against the growing influence of gangs. Political crisisHaiti has also been mired in a political crisis in recent months.President Jovenel Moïse argues his mandate ends on 7 February 2022, while opponents say it ended on 7 February 2021. The disagreement stems from the fact that Moïse was elected in a vote that was invalidated due to fraud and then re-elected one year later. The country has been without a parliament since last year, since when Moïse has been governing by decree. The president has also said he plans to hold a constitutional referendum in June. (with newswires)

  • Correction: Key dates for the Yara International ASA 2020 dividend

    Oslo, 12 April 2021: Reference is made to Yara’s stock exchange release dated 9 April 2021 regarding the Ordinary General Meeting and dividend of NOK 20 per share. The following key dates will apply for the additional dividend: Ex dividend NOK 20.00 as of: 7 May 2021 Record date: 10 May 2021 Dividend payment date: 19 May 2021 ADR dividend payment date: 26 May 2021 Contact Thor Giæver, Investor Relations Cellular: (+47) 480 75 356 E-mail: thor.giaver@yara.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger, we pursue a strategy of sustainable value growth, promoting climate-friendly and high-yielding crop nutrition solutions for the world’s farming community and food industry. Yara’s ambition is to be the Crop Nutrition Company for the Future. We are committed to creating value for our customers, shareholders and society at large, as we work to develop a more sustainable food value chain. To achieve our ambition, we have taken the lead in developing digital farming tools for precision farming, and work closely with partners throughout the food value chain to improve the efficiency and sustainability of agriculture and food production. Founded in 1905 to solve the emerging famine in Europe, Yara has established a unique position as the industry’s only global crop nutrition company. With our integrated business model and a worldwide presence of around 16,000 employees and operations in over 60 countries, we offer a proven track record of responsible and reliable returns. In 2020, Yara reported revenues of USD 11.6 billion. www.yara.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

  • Drivers License singer Olivia Rodrigo gets parking ticket

    Olivia Rodrigo has reacted with amusement after she was snapped with a ticket for a parking violation in Los Angeles.The Drivers Licence hitmaker posted a snapshot of an official red and white City of Los Angeles Parking Violation envelope to her Instagram story on Sunday, captioning it: "Damn this driving s**t isn’t all fun and games."The High School Musical star did not elaborate on what she did to earn the ticket.It's not the first time Rodrigo has had an ironic mishap with her car - in March the singer recounted to radio station 94.5 PST that she had struggled to pass her driver's licence test."Essentially, the time I got my drivers license it was my fourth try, which is really sad," she began, sharing that the first appointment for her test was cancelled because of Covid-19, and the second she had to reschedule because she was filming High School Musical: The Musical: The Series.Rodrigo explained she flew from Utah to LA just to have another go but ran into a hiccup."I'm sitting in the car and the guy comes by and he's checking my lights and stuff like that, and he goes, 'Ok, honk your horn now'. And I go to honk my horn and the horn doesn't work on my mum's car and she had no idea that the horn doesn't work on her car because she never uses her horn because she's the calmest person in the whole world," she recalled.The car was deemed unsafe for the test, but Rodrigo finally passed on her fourth try and got her licence."I got there eventually!" she laughed.

  • Hugh Jackman pays tribute to his wife on 25th wedding anniversary

    Hugh Jackman said he was "destined" to be with his wife Deborra-Lee Furness as he celebrated his 25th wedding anniversary on Sunday.The Greatest Showman actor paid a touching tribute to his partner on Sunday by sharing a series of sweet throwback snaps from their wedding day and explaining just how important Deborra-Lee is to him."Being married to you Deb is as natural as breathing," he wrote on his Instagram account, accompanied by five photos from their wedding. "From nearly the moment we met... I knew our destiny was to be together. In our 25 years - our love has only grown deeper. The fun, excitement and adventure more exhilarating; the learning even greater. I'm forever grateful to share our love, our life - and, our family together. We've only just begun."Hugh met Deborra-Lee on the set of Australian TV show Corelli in 1995, with the star proposing after dating for just four months, and the pair went on to tie the knot in April 1996 in Australia.The couple has two adopted children together, and Hugh has previously shared that the secret to their successful relationship is never spending more than two weeks apart.The 52-year-old actor has never been afraid to publicly show his affection for his wife, serenading Deborra-Lee with All the Way by Frank Sinatra - the song the couple danced to at its wedding - during a concert in 2019.

  • ‘Mother of God!’: Line of Duty fans thrown into disarray after explosive fourth episode

    Warning: this article contains spoilers

  • Las Vegas to ban ‘non-functional’ grass in bid to save water

    Officials estimate that removing this grass could reduce annual water consumption of the region by about 15%

  • Fremantle Acquires 100% of Israeli Producer Abot Hameiri (EXCLUSIVE)

    Fremantle has taken full ownership of Abot Hameiri, the Israeli production company behind international drama hit “Shtisel” and original formats “Power Couple” and “Hear Me, Love Me, See Me.” Abot Hameiri is also the Israeli producer for global formats such as “Got Talent,” “Survivor” and “The X Factor.” The latter will return on Reshet 13 […]

  • Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme

    Company Announcement No. 18/2021 Copenhagen, 12 April 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 6 April to 9 April 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement412,430 50,724,141 6 April 202120,290122.902,495,467 7 April 202119,637124.962,453,847 8 April 20215,760125.02720,131 9 April 202111,068127.581,412,047Accumulated under the program469,185 57,805,633 A detailed overview of transactions during the period 6 April – 9 April 2021 is attached to this announcement. Following the above transactions STG owns a total of 3,703,433 treasury shares, corresponding to 3.70% of the total share capital. For further information, please contact:Investors: Torben Sand, Head of Investor Relations, phone: +45 5084 7222 or torben.sand@st-group.com Media: Simon Mehl Augustesen, Director of Group Communications, phone: +1 484-379-8725 or simon.augustesen@st-group.com Attachments Company Announcement no 18 2021 9 APR 2021 PUBLIC_SBB_SCANDINAVIAN TOBACCO GROUP